| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Megakaryoblastic, Acute | 2 | 2022 | 44 | 1.530 |
Why?
|
| Proto-Oncogene Proteins B-raf | 7 | 2017 | 1327 | 1.160 |
Why?
|
| Biomarkers, Tumor | 13 | 2024 | 10676 | 0.950 |
Why?
|
| Matrix Metalloproteinase 14 | 4 | 2010 | 20 | 0.810 |
Why?
|
| Blood Platelet Disorders | 1 | 2022 | 35 | 0.790 |
Why?
|
| Carcinoma, Papillary | 2 | 2013 | 566 | 0.670 |
Why?
|
| Melanoma | 6 | 2016 | 5594 | 0.660 |
Why?
|
| Sarcoma, Myeloid | 1 | 2019 | 93 | 0.640 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2022 | 478 | 0.600 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2022 | 388 | 0.600 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2020 | 347 | 0.570 |
Why?
|
| Mediastinal Neoplasms | 1 | 2020 | 427 | 0.540 |
Why?
|
| Testicular Neoplasms | 1 | 2020 | 560 | 0.530 |
Why?
|
| Carcinoma, Small Cell | 1 | 2018 | 427 | 0.520 |
Why?
|
| Extracellular Matrix | 2 | 2009 | 524 | 0.510 |
Why?
|
| cdc42 GTP-Binding Protein | 3 | 2010 | 46 | 0.500 |
Why?
|
| Thyroid Neoplasms | 3 | 2018 | 1876 | 0.500 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2024 | 1736 | 0.500 |
Why?
|
| Mutation | 15 | 2023 | 15891 | 0.470 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2021 | 550 | 0.460 |
Why?
|
| Genetic Techniques | 1 | 2014 | 151 | 0.450 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 1400 | 0.440 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2014 | 168 | 0.410 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2016 | 618 | 0.360 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2023 | 2354 | 0.350 |
Why?
|
| Oncogene Proteins, Fusion | 3 | 2022 | 796 | 0.340 |
Why?
|
| Skin Neoplasms | 3 | 2015 | 4883 | 0.340 |
Why?
|
| Hepatoblastoma | 2 | 2022 | 222 | 0.330 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2016 | 5563 | 0.320 |
Why?
|
| Medical Oncology | 2 | 2014 | 1462 | 0.320 |
Why?
|
| ErbB Receptors | 2 | 2016 | 2376 | 0.310 |
Why?
|
| Humans | 48 | 2024 | 270200 | 0.290 |
Why?
|
| Molecular Targeted Therapy | 2 | 2014 | 2389 | 0.290 |
Why?
|
| Genetic Testing | 2 | 2019 | 1695 | 0.280 |
Why?
|
| Neoplasms | 5 | 2022 | 15882 | 0.280 |
Why?
|
| Ovarian Neoplasms | 2 | 2022 | 4784 | 0.270 |
Why?
|
| Child | 14 | 2024 | 30493 | 0.270 |
Why?
|
| DNA Mutational Analysis | 4 | 2019 | 2355 | 0.270 |
Why?
|
| Neoplasm Invasiveness | 4 | 2013 | 4041 | 0.260 |
Why?
|
| GTP-Binding Proteins | 1 | 2006 | 342 | 0.250 |
Why?
|
| Repressor Proteins | 3 | 2022 | 1711 | 0.250 |
Why?
|
| Genomics | 2 | 2021 | 2825 | 0.240 |
Why?
|
| Transcriptome | 1 | 2013 | 1948 | 0.240 |
Why?
|
| Kidney Neoplasms | 2 | 2019 | 3106 | 0.230 |
Why?
|
| Lung Neoplasms | 3 | 2016 | 12014 | 0.230 |
Why?
|
| Immunohistochemistry | 8 | 2017 | 7647 | 0.230 |
Why?
|
| Quality Control | 2 | 2016 | 463 | 0.220 |
Why?
|
| Lipids | 1 | 2006 | 653 | 0.210 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 1948 | 0.210 |
Why?
|
| Collagen | 4 | 2010 | 727 | 0.210 |
Why?
|
| Sertoli-Leydig Cell Tumor | 1 | 2022 | 20 | 0.200 |
Why?
|
| Fibroma | 1 | 2022 | 86 | 0.200 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 7261 | 0.200 |
Why?
|
| Endonucleases | 2 | 2013 | 184 | 0.200 |
Why?
|
| Carcinoma | 1 | 2013 | 2607 | 0.190 |
Why?
|
| Sequence Analysis, DNA | 4 | 2022 | 2570 | 0.190 |
Why?
|
| Burkitt Lymphoma | 1 | 2024 | 350 | 0.190 |
Why?
|
| Adolescent | 11 | 2024 | 32657 | 0.190 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2013 | 2387 | 0.180 |
Why?
|
| Ribonuclease III | 1 | 2022 | 182 | 0.180 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2022 | 213 | 0.180 |
Why?
|
| Signal Transduction | 4 | 2015 | 12097 | 0.180 |
Why?
|
| Brain Neoplasms | 3 | 2023 | 4948 | 0.180 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2022 | 256 | 0.170 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 274 | 0.170 |
Why?
|
| Cyclin B | 1 | 2019 | 69 | 0.170 |
Why?
|
| Ligands | 1 | 2022 | 1015 | 0.170 |
Why?
|
| DNA Polymerase II | 1 | 2019 | 58 | 0.170 |
Why?
|
| Sensitivity and Specificity | 4 | 2016 | 5155 | 0.170 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2019 | 43 | 0.170 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 117 | 0.170 |
Why?
|
| Hemangiosarcoma | 1 | 2022 | 238 | 0.170 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2019 | 35 | 0.170 |
Why?
|
| Leukemia, Myelomonocytic, Juvenile | 1 | 2019 | 31 | 0.160 |
Why?
|
| Chernobyl Nuclear Accident | 1 | 2018 | 14 | 0.160 |
Why?
|
| Ependymoma | 1 | 2021 | 265 | 0.160 |
Why?
|
| Cytogenetic Analysis | 1 | 2020 | 574 | 0.160 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2020 | 205 | 0.160 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2022 | 678 | 0.150 |
Why?
|
| Translocation, Genetic | 1 | 2024 | 1285 | 0.150 |
Why?
|
| Granulosa Cell Tumor | 1 | 2018 | 81 | 0.150 |
Why?
|
| Herpesvirus 4, Human | 1 | 2022 | 957 | 0.150 |
Why?
|
| Codon, Nonsense | 1 | 2018 | 159 | 0.150 |
Why?
|
| Hypercalcemia | 1 | 2018 | 145 | 0.150 |
Why?
|
| Radiation Exposure | 1 | 2018 | 71 | 0.150 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2022 | 637 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 1542 | 0.150 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2019 | 231 | 0.140 |
Why?
|
| Cell Movement | 3 | 2009 | 2472 | 0.140 |
Why?
|
| Loss of Heterozygosity | 1 | 2018 | 623 | 0.140 |
Why?
|
| Transcription Factors | 2 | 2022 | 5435 | 0.140 |
Why?
|
| Pyridazines | 1 | 2019 | 319 | 0.130 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2016 | 59 | 0.130 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2016 | 82 | 0.130 |
Why?
|
| Limit of Detection | 1 | 2016 | 85 | 0.130 |
Why?
|
| Thrombocytosis | 1 | 2017 | 142 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2015 | 9038 | 0.130 |
Why?
|
| DNA Helicases | 1 | 2018 | 450 | 0.130 |
Why?
|
| Oxo-Acid-Lyases | 1 | 2015 | 4 | 0.130 |
Why?
|
| Octamer Transcription Factor-1 | 1 | 2015 | 10 | 0.130 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 1092 | 0.130 |
Why?
|
| Male | 17 | 2024 | 127960 | 0.130 |
Why?
|
| Gene Rearrangement | 2 | 2020 | 812 | 0.130 |
Why?
|
| Heterozygote | 1 | 2018 | 1053 | 0.130 |
Why?
|
| Paraffin Embedding | 1 | 2016 | 221 | 0.130 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2022 | 913 | 0.130 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 1070 | 0.130 |
Why?
|
| Calreticulin | 1 | 2015 | 87 | 0.120 |
Why?
|
| DNA Copy Number Variations | 1 | 2022 | 1553 | 0.120 |
Why?
|
| Liver Neoplasms | 2 | 2022 | 4803 | 0.120 |
Why?
|
| Female | 19 | 2024 | 148466 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2018 | 3654 | 0.120 |
Why?
|
| Ovary | 1 | 2018 | 688 | 0.120 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2015 | 161 | 0.120 |
Why?
|
| Receptor, ErbB-2 | 2 | 2016 | 2650 | 0.120 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2015 | 128 | 0.120 |
Why?
|
| Lymphoma, B-Cell | 1 | 2021 | 929 | 0.120 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2015 | 129 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2022 | 2610 | 0.120 |
Why?
|
| Medulloblastoma | 1 | 2019 | 572 | 0.110 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2017 | 283 | 0.110 |
Why?
|
| Endothelial Cells | 2 | 2010 | 1037 | 0.110 |
Why?
|
| Imidazoles | 1 | 2019 | 1058 | 0.110 |
Why?
|
| Thymidylate Synthase | 1 | 2013 | 57 | 0.110 |
Why?
|
| Lipoma | 1 | 2013 | 93 | 0.110 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2016 | 2310 | 0.110 |
Why?
|
| Survivors | 1 | 2018 | 1022 | 0.110 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2014 | 202 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 1348 | 0.110 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2012 | 16 | 0.110 |
Why?
|
| Hodgkin Disease | 1 | 2021 | 1484 | 0.100 |
Why?
|
| Azacitidine | 1 | 2019 | 1217 | 0.100 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2012 | 29 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2021 | 1539 | 0.100 |
Why?
|
| DNA-Binding Proteins | 3 | 2019 | 4999 | 0.100 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2018 | 743 | 0.100 |
Why?
|
| DNA Primers | 1 | 2014 | 1497 | 0.100 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2016 | 496 | 0.100 |
Why?
|
| Sarcoma | 1 | 2022 | 1836 | 0.100 |
Why?
|
| Leukemia | 1 | 2020 | 1718 | 0.100 |
Why?
|
| Specialties, Surgical | 1 | 2013 | 134 | 0.100 |
Why?
|
| Stomach Neoplasms | 2 | 2013 | 2254 | 0.090 |
Why?
|
| Adenocarcinoma | 3 | 2014 | 7878 | 0.090 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2012 | 332 | 0.090 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2012 | 180 | 0.090 |
Why?
|
| Satellite Cells, Skeletal Muscle | 1 | 2009 | 35 | 0.080 |
Why?
|
| Models, Biological | 2 | 2009 | 3195 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1199 | 0.080 |
Why?
|
| Exons | 1 | 2013 | 1381 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 2161 | 0.080 |
Why?
|
| Infant | 3 | 2019 | 13939 | 0.080 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2009 | 121 | 0.080 |
Why?
|
| Mutation, Missense | 1 | 2014 | 1190 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2021 | 3662 | 0.080 |
Why?
|
| Child, Preschool | 3 | 2019 | 17008 | 0.080 |
Why?
|
| Prognosis | 6 | 2019 | 22465 | 0.080 |
Why?
|
| Blood Vessels | 1 | 2009 | 232 | 0.080 |
Why?
|
| Apoptosis | 1 | 2022 | 7750 | 0.080 |
Why?
|
| Neovascularization, Physiologic | 1 | 2010 | 345 | 0.070 |
Why?
|
| Myeloproliferative Disorders | 1 | 2015 | 881 | 0.070 |
Why?
|
| Base Sequence | 1 | 2014 | 5433 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 10359 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 6179 | 0.070 |
Why?
|
| Cholangiocarcinoma | 1 | 2012 | 501 | 0.070 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2006 | 11 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 3439 | 0.070 |
Why?
|
| Sphingosine | 1 | 2006 | 59 | 0.070 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2006 | 89 | 0.070 |
Why?
|
| Endometrial Neoplasms | 1 | 2016 | 1383 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 5140 | 0.070 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2006 | 110 | 0.070 |
Why?
|
| Matrix Metalloproteinases | 1 | 2006 | 138 | 0.070 |
Why?
|
| Lysophospholipids | 1 | 2006 | 148 | 0.070 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 2911 | 0.060 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 2634 | 0.060 |
Why?
|
| Young Adult | 4 | 2022 | 22115 | 0.060 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2009 | 907 | 0.060 |
Why?
|
| Aged | 7 | 2016 | 73069 | 0.060 |
Why?
|
| RNA, Small Interfering | 2 | 2009 | 2197 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 1 | 2022 | 5245 | 0.060 |
Why?
|
| Adult | 7 | 2018 | 81643 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 1899 | 0.060 |
Why?
|
| Cell Line, Tumor | 3 | 2022 | 14805 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 3698 | 0.060 |
Why?
|
| Germ-Line Mutation | 2 | 2019 | 1099 | 0.060 |
Why?
|
| Middle Aged | 7 | 2016 | 89983 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2024 | 329 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2024 | 287 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2009 | 1289 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 30908 | 0.050 |
Why?
|
| Receptor, trkB | 1 | 2021 | 52 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2022 | 265 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2024 | 4830 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2006 | 5758 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2021 | 453 | 0.040 |
Why?
|
| Multiple Endocrine Neoplasia Type 2b | 1 | 2018 | 53 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2019 | 235 | 0.040 |
Why?
|
| Pancreas | 1 | 2022 | 744 | 0.040 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2022 | 706 | 0.040 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 2018 | 126 | 0.040 |
Why?
|
| Germ Cells | 1 | 2019 | 330 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2019 | 282 | 0.040 |
Why?
|
| Pancreatectomy | 1 | 2022 | 696 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2023 | 2362 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2010 | 5690 | 0.040 |
Why?
|
| Leukocytosis | 1 | 2017 | 113 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 1095 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 9043 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2018 | 374 | 0.030 |
Why?
|
| Acetoacetates | 1 | 2015 | 22 | 0.030 |
Why?
|
| Polyps | 1 | 2016 | 71 | 0.030 |
Why?
|
| Pathology, Surgical | 1 | 2016 | 78 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2022 | 2032 | 0.030 |
Why?
|
| Nephrectomy | 1 | 2019 | 797 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2019 | 1051 | 0.030 |
Why?
|
| Cerebellar Neoplasms | 1 | 2019 | 478 | 0.030 |
Why?
|
| Pelvis | 1 | 2016 | 383 | 0.030 |
Why?
|
| Antibodies, Neoplasm | 1 | 2015 | 273 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2013 | 5091 | 0.030 |
Why?
|
| Neoplasms, Adipose Tissue | 1 | 2013 | 9 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2013 | 4951 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 6256 | 0.030 |
Why?
|
| Remission Induction | 1 | 2019 | 3649 | 0.030 |
Why?
|
| Time Factors | 1 | 2006 | 12993 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 657 | 0.030 |
Why?
|
| Endometrium | 1 | 2016 | 460 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 10256 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2016 | 9455 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 14622 | 0.020 |
Why?
|
| Recurrence | 1 | 2019 | 4870 | 0.020 |
Why?
|
| Uterus | 1 | 2016 | 798 | 0.020 |
Why?
|
| Algorithms | 1 | 2022 | 3917 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 695 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2013 | 580 | 0.020 |
Why?
|
| Microscopy, Video | 1 | 2009 | 32 | 0.020 |
Why?
|
| Integrin alpha Chains | 1 | 2009 | 23 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2009 | 137 | 0.020 |
Why?
|
| Laminin | 1 | 2009 | 210 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 7364 | 0.020 |
Why?
|
| Biocatalysis | 1 | 2009 | 64 | 0.020 |
Why?
|
| Receptors, Growth Factor | 1 | 2009 | 157 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 2420 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2009 | 156 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 2321 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 1815 | 0.020 |
Why?
|
| Cues | 1 | 2009 | 200 | 0.020 |
Why?
|
| Phenotype | 1 | 2019 | 6481 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2009 | 580 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2013 | 936 | 0.020 |
Why?
|
| Genotype | 1 | 2015 | 4251 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2010 | 573 | 0.020 |
Why?
|
| Antibodies | 1 | 2010 | 808 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2009 | 1027 | 0.020 |
Why?
|
| Cell Communication | 1 | 2009 | 513 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2009 | 696 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 4354 | 0.020 |
Why?
|
| Mice | 2 | 2022 | 35547 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2009 | 658 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 5765 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 3353 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 4936 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2009 | 1418 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 1467 | 0.010 |
Why?
|
| Animals | 2 | 2022 | 61965 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2010 | 2117 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 15196 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2013 | 39688 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2010 | 2922 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2013 | 5673 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 16643 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2012 | 13362 | 0.010 |
Why?
|